Skip to main content

Table 2 Clinical data of 212 HBV-related HCC patients in the GSE14520 of GEO database

From: Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma

Variables

Patient (n = 212)

OS

No. of events

MST (months)

HR (95% CI)

P

Age (years)

     

 ≤ 60

175

69

NA

1

 

 > 60

37

13

NA

0.864 (0.478–1.564)

0.63

Gender

     

 Female

29

8

NA

1

 

 Male

183

74

NA

1.704 (0.821–3.534)

0.152

Multinodular

     

 Single

167

59

NA

1

 

 Multiple

45

23

47.9

1.607 (0.992–2.604)

0.054

Tumor sizea

     

 ≤ 5 cm

137

46

NA

1

 

 > 5 cm

74

36

53.3

1.975 (1.274–3.060)

0.002

Cirrhosis

     

 No

17

2

NA

1

 

 Yes

195

80

NA

4.335 (1.065–17.638)

0.041

BCLC stage

     

 0

20

2

NA

1

 

 A

143

48

NA

4.119 (1.001–16.951)

0.050

 B

22

12

46.1

8.992 (2.005–40.320)

0.004

 C

27

20

13.6

18.993 (4.419–81.632)

< 0.001

Serum AFPb

     

 ≤ 300 ng/ml

115

39

NA

1

 

 > 300 ng/ml

94

43

NA

1.546 (1.002–2.385)

0.049

ALT

     

 < 50U/L

124

46

NA

1

 

 ≥ 50U/L

88

36

NA

1.095 (0.708–1.693)

0.684

TNM stage

     

 I

89

20

NA

1

 

 II

76

32

NA

2.214 (1.265–3.873)

0.005

 III or IV

47

30

18

5.197 (2.930–9.218)

< 0.001

  1. HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; MST, median survival time; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available
  2. aInformation of tumor size was unavailable in 1 patients
  3. bInformation of serum AFP was unavailable in 3 patients
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us